These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28949468)

  • 1. Don't Discount Societal Value in Cost-Effectiveness Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness".
    Hall W
    Int J Health Policy Manag; 2017 Sep; 6(9):543-545. PubMed ID: 28949468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness.
    Baltussen R; Jansen MP; Mikkelsen E; Tromp N; Hontelez J; Bijlmakers L; Van der Wilt GJ
    Int J Health Policy Manag; 2016 Nov; 5(11):615-618. PubMed ID: 27801355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-Informed Deliberative Processes for Universal Health Coverage: Broadening the Scope Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness".
    Gopinathan U; Ottersen T
    Int J Health Policy Manag; 2017 Aug; 6(8):473-475. PubMed ID: 28812847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priority Setting for Universal Health Coverage: We Need to Focus Both on Substance and on Process Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, not Just More Evidence on Cost-Effectiveness".
    Lauer JA; Rajan D; Bertram MY
    Int J Health Policy Manag; 2017 Oct; 6(10):601-603. PubMed ID: 28949475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Technology Assessment: Global Advocacy and Local Realities Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness".
    Chalkidou K; Li R; Culyer AJ; Glassman A; Hofman KJ; Teerawattananon Y
    Int J Health Policy Manag; 2017 Apr; 6(4):233-236. PubMed ID: 28812807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-Informed Deliberative Processes for UHC: Progress, Potential and Prudence Comment on "Evidence-Informed Deliberative Processes for Health Benefit Package Design - Part II: A Practical Guide".
    Gopinathan U
    Int J Health Policy Manag; 2023; 12():7541. PubMed ID: 37579471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing Country Experiences for Health Benefit Package Design: Evidence-Informed Deliberative Processes and Experiences From the Joint Learning Network Comment on "Evidence-Informed Deliberative Processes for Health Benefit Package Design - Part II: A Practical Guide".
    Nagpal S; Ahluwalia N; Hashiguchi LO; McGee K; Lutalo M
    Int J Health Policy Manag; 2023; 12():7856. PubMed ID: 38618786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".
    Gopinathan U; Ottersen T; Cyr PR; Chalkidou K
    Int J Health Policy Manag; 2021 Mar; 10(4):232-236. PubMed ID: 32772012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Priority Setting Meets Multiple Streams: A Match to Be Further Examined? Comment on "Introducing New Priority Setting and Resource Allocation Processes in a Canadian Healthcare Organization: A Case Study Analysis Informed by Multiple Streams Theory.
    Cumming JM
    Int J Health Policy Manag; 2016 Aug; 5(8):497-499. PubMed ID: 27694663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HTA Agencies Need Evidence-Informed Deliberative Processes Comment on "Use of Evidence-Informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".
    Schlander M
    Int J Health Policy Manag; 2021 Mar; 10(3):158-161. PubMed ID: 32610783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-criteria decision analysis for setting priorities on HIV/AIDS interventions in Thailand.
    Youngkong S; Teerawattananon Y; Tantivess S; Baltussen R
    Health Res Policy Syst; 2012 Feb; 10():6. PubMed ID: 22339981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value Assessment Frameworks for HTA Agencies: The Organization of Evidence-Informed Deliberative Processes.
    Baltussen R; Jansen MPM; Bijlmakers L; Grutters J; Kluytmans A; Reuzel RP; Tummers M; der Wilt GJV
    Value Health; 2017 Feb; 20(2):256-260. PubMed ID: 28237205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three Approaches to Improve a Practical Guide on Evidence-Informed Deliberative Processes for Health Benefit Package Design Comment on "Evidence-Informed Deliberative Processes for Health Benefit Package Design - Part II: A Practical Guide".
    Guzman J
    Int J Health Policy Manag; 2023; 12():7502. PubMed ID: 36086853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicriteria decision analysis for including health interventions in the universal health coverage benefit package in Thailand.
    Youngkong S; Baltussen R; Tantivess S; Mohara A; Teerawattananon Y
    Value Health; 2012; 15(6):961-70. PubMed ID: 22999148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 18. Challenges and Opportunities for Deliberative Processes for Healthcare Decision-Making Comment on "Evidence-Informed Deliberative Processes for Health Benefit Package Design - Part II: A Practical Guide".
    Bond K
    Int J Health Policy Manag; 2023; 12():7458. PubMed ID: 35988028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Institutionalizing Evidence-Informed Priority Setting for Universal Health Coverage: Lessons From Indonesia.
    Sharma M; Teerawattananon Y; Luz A; Li R; Rattanavipapong W; Dabak S
    Inquiry; 2020; 57():46958020924920. PubMed ID: 32513029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of Evidence-Informed Deliberative Processes for Health Benefit Package Design in Kazakhstan.
    Oortwijn W; Surgey G; Novakovic T; Baltussen R; Kosherbayeva L
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.